Aromatase inhibitors can cause hair loss as a side effect by reducing estrogen production, which disrupts the hair growth cycle. This occurs in about 10% of users, typically within the first few months of treatment.
Aromatase inhibitors block the enzyme aromatase, which converts testosterone to estrogen. By lowering estrogen levels, they slow the growth of hormone-receptor-positive breast cancers. Common drugs in this class include anastrozole, letrozole, and exemestane.
Hair loss from aromatase inhibitors usually presents as diffuse thinning rather than complete baldness. Unlike the sudden shedding seen with chemotherapy, this type of hair loss progresses gradually over weeks or months.
| Type | Characteristics | Onset |
|---|---|---|
| Diffuse Thinning | Even hair loss across scalp | Gradual (weeks to months) |
| Patchy Loss | Irregular bald spots | Variable |
Estrogen is important for the hair growth cycle. By suppressing estrogen, aromatase inhibitors can shorten the anagen (growth) phase and prolong the telogen (resting) phase, leading to increased shedding. A study published in the Journal of Clinical Oncology found that 8% of women taking aromatase inhibitors experienced noticeable hair thinning.
For my mother, who took anastrozole for three years, a combination of minoxidil foam and a gentle scalp massage helped maintain her hair density. The American Cancer Society recommends using mild shampoos, avoiding tight hairstyles, and considering wigs or scarves if needed.
If hair loss becomes severe or is accompanied by other symptoms like rash or itching, consult your healthcare provider. They may recommend adjusting your treatment plan or referring you to a dermatologist. In rare cases, hair mites or other conditions could contribute to hair loss.